Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

DACHS - IMPACT - Prognosis

IMPACT: Improving long-term prognosis and quality of life of patients with colorectal cancer

Despite improvements in treatment of colorectal cancer (CRC), patient variability in treatment outcome is still frequently observed. Treatment outcome mainly depends on stage at diagnosis but there is also major variation in prognosis within groups of patients with the same tumor stage which is largely unexplained. Surgery is the primary treatment in CRC. Depending on CRC stage, patients receive radiation or chemotherapy in advance or after surgery. Several chemotherapeutic agents are approved in Germany. Individual differences in patients' response to therapy and in survival after specific types of chemotherapy might be in part influenced by genetic variation such as in drug metabolism and tumour immune response.
Candidate gene as well as genome-wide association studies will be conducted to identify genetic variants which affect overall as well as progression free survival according to chemotherapy type.

This project involves patients of the DACHS study and is part of a network investigating long-term prognosis in colorectal cancer patients called IMPACT. Replication of promising findings will be carried out in collaboration with the International Survival Analysis in Colorectal cancer Consortium (ISACC).

Division of Clinical Epidemiology and Aging Research (DKFZ)
ISACC (Fred Hutchinson Cancer Research Center Seattle, Washington, USA)

to top
powered by webEdition CMS